Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Daiichi Sankyo Ltd ADR (OP:DSNKY)

21.88 +0.46 (+2.15%)
Streaming Delayed Price Updated: 11:48 AM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Daiichi Sankyo Ltd ADR

< Previous 1 2 3 Next >
News headline image
AstraZeneca-Daiichi Sankyo Share Detailed Enhertu Data In Gastric Cancer ↗
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY) announced detailed results from the positive DESTINY-Gastric02 Phase 2 trial of Enhertu... 
Via Benzinga
News headline image
AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer ↗
AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo Co Ltd (OTC: DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3... 
Via Benzinga
News headline image
Daiichi Sankyo - AstraZeneca Start Dosing In Head-To-Head Stomach Cancer Trial With Enhertu ↗
Daiichi Sankyo Co Ltd (OTC: DSKYF) and AstraZeneca plc (NASDAQ: AZN) have dosed the first patient in DESTINY-Gastric04, Phase 3 trial of Enhertu (... 
Via Benzinga
News headline image
Daiichi Sankyo To Stop Testing Inhaled Nafamostat In COVID-19 Patients In Japan ↗
Daiichi Sankyo Co Ltd (OTC: DSNKY) said it was halting the development of an existing drug for the treatment of COVID-19 without citing a reason. However, the... 
Via Benzinga
News headline image
Nipro To Provide Fill, Finish Services For AstraZeneca COVID-19 Shots In Japan: Reuters ↗
Japan's Nipro Corporation has signed an agreement to supply AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine in Japan, reports Reuters. Nipro... 
Via Benzinga
News headline image
AstraZeneca, Daiichi Sankyo Partnered ADC Shows Promise In Hard-To-Treat Breast Cancer ↗
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OCTMKTS: DSNKY) have announced an update from their second antibody-drug conjugate (ADC) program... 
Via Benzinga
News headline image
LogicBio Therapeutics, CANbridge Ink Partnership For Development Of Gene Therapy Candidates ↗
CANbridge Pharmaceuticals Inc has entered into a strategic collaboration and licensing agreement with LogicBio Therapeutics Inc (NASDAQ: LOGC) to... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.